Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers

Although the field of pharmacogenetics has existed for decades, practioners have been slow to implement pharmacogenetic testing in clinical care. Numerous publications describe the barriers to clinical implementation of pharmacogenetics. Recently, several freely available resources have been develop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annual review of pharmacology and toxicology 2015-01, Vol.55 (1), p.89-106
Hauptverfasser: Dunnenberger, Henry M, Crews, Kristine R, Hoffman, James M, Caudle, Kelly E, Broeckel, Ulrich, Howard, Scott C, Hunkler, Robert J, Klein, Teri E, Evans, William E, Relling, Mary V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although the field of pharmacogenetics has existed for decades, practioners have been slow to implement pharmacogenetic testing in clinical care. Numerous publications describe the barriers to clinical implementation of pharmacogenetics. Recently, several freely available resources have been developed to help address these barriers. In this review, we discuss current programs that use preemptive genotyping to optimize the pharmacotherapy of patients. Array-based preemptive testing includes a large number of relevant pharmacogenes that impact multiple high-risk drugs. Using a preemptive approach allows genotyping results to be available prior to any prescribing decision so that genomic variation may be considered as an inherent patient characteristic in the planning of therapy. This review describes the common elements among programs that have implemented preemptive genotyping and highlights key processes for implementation, including clinical decision support.
ISSN:0362-1642
1545-4304
DOI:10.1146/annurev-pharmtox-010814-124835